The goal of this investigation is the development a new biocompatible intra-vaginal ring (IVR) composed of nanoporous poly (diol citrate) elastomeres for a sustained release of nonhormonal contraceptives, namely ferrous gluconate to cause spermiostasis, ascorbic acid to increase cervical mucus viscosity, and a mixture of ampholines and/or poly L-glutamic acid (PGLA) buffer to sustain the pH at 4 to cause spermiostasis within 30 seconds, for the prevention of undesired pregnancy. The IVR of 5.5 cm in diameter and a rim of 0.5 cm is cast in a mold. The daily eluates of the IVR are tested for pH, spermiostatic and/or spermicidal activity and effect on the viscosity of cervical mucus. Results of this study are efficacious in vitro; the IVR has a shelf life of one year and provides the basis for the newly developed IVR containing non-hormonal contraceptives for in vivo use in women to prevent undesired pregnancy as well as pelvic and HIV infection simultaneously or HIV infection alone.
Introduction
Contraception is the term used to describe methods used for preventing undesired pregnancy. Hormonal methods include combined oral contraceptives (COC), mini pills, injections, implants, hormonal intrauterine devices (Mirena), and the hormonal vaginal ring (NuvaRing ® ) once a month [1] . Hormonal contraceptives, on the other hand, are the most convenient, but long-term use of these products can lead to an altered hormonal state, disrupt endocrine homeostasis, and are associated with increased incident of cervical cancer [2] . Non-hormonal methods are natural family planning methods, the withdrawal technique (coitus interruptus) [3] , male condoms, cervical caps, female condoms and spermicide gels [4] . There remains a significant failure rate mainly due to improper use of these methods. Female condoms are also available but not very popular. Surgical procedures, namely male and female sterilization, are invasive, costly, and difficult to reverse. Notwithstanding the development in the methods of family planning, the paradox exists that the rates of undesired pregnancy, pregnancy termination, and pelvic diseases, including HIV, are increasing globally. To overcome the above and to provide a safe and efficacious means of protection the intra-vaginal ring (IVR) containing non-hormonal agents described here can be an effective non-hormonal method that can provide protection from month to month to coincide with the menstrual cycle when women may change to a new ring. This new IVR, as compared to the earlier HEMA and acacia intra-vaginal rings [5, 6] , provide a better cost effective, reliant mode of family planning that benefits maternal-fetal health and overall quality of life and may also be used to deliver microbicides [7] .
Materials and Methods

Preparation and properties of nanoporous poly (diol citrate) elastomeric hydrogel IVR
The nanoporous elastomere IVR (Figure 1 ) retained its flexibility for one year (Figures 2 and 3) indicating shelf life for ease of use: The IVR rings are made by using nanoporous elastomeres of biodegradable, hydrophilic, and biocompatible polymer hydrogel using poly (diol citrates). The biodegradable nano-pores act to control the release rates of the drugs [8, 9] . 1,8-Octanediol, citric acid and ascorbic acid were used in a 10:10:1 molar ratio. were mixed and heated at 165°C for 10 minutes, followed by 140°C for an additional 60 minutes for prepolymerization. The formed poly-1,8-octanediol-co-citric acid-co-ascorbate (POCA) prepolymer was dissolved in 100% ethanol and purified by precipitation in a minimum 5:1 water:prepolymer solution ratio, followed by lyophilization for 3 days. The POCA prepolymer was dissolved at a 30% w/w solution in 100% ethanol and ferrous gluconate (0.8 g per ring), ascorbic acid (0.7 g per ring), and pharmalyte (0.5 cc per ring) was mixed in by simple dissolution of the compound in the prepolymer solution. This mixture was then left overnight for ethanol evaporation and the resulting, viscous polymer poured into a metal mold for a ring with inner diameter of 55 mm and cross-sectional diameter of 5 mm. The ring was post-polymerized for 4 days at 80°C, after which the ring was gently removed from the mold and washed with ethanol (3x).
In vitro and in vivo evaluation of poly-diol citrates have shown cell and tissue compatibility [10] . Ferrous gluconate and ascorbic acid was purchased from Sigma-Aldrich Co., and the mixture of polyamino-polcarboxylic acid (Ampholines) was purchased from Amersham Biosciences (Uppsala, Sweden) and Poly L-Glutamic Acid (PLGA):sodium bicarbonate buffer was supplied by the Guilin Peptide Technology Limited, China, for use as a pH stabilizer.
Collection of daily eluates of the IVR and analysis of release rates [5,6]:
The IVR is placed in a petri dish containing 10 ml of phosphate buffered saline (PBS) or vaginal fluid stimulant [11] . The petri dish is closed airtight and placed on a shaker at low speed. Eluates are collected daily and the eluant is replenished over a 30 day period. The eluates are ultra-filtered and stored at 20°C until analyzed. The IVR is stored at room temperature under sterile conditions and tested again after one year for an additional 30 days for shelf life. The concentration of the ferrous gluconate is determined as described earlier [12] . In this method, Phenanthroline, when added to the eluates forms an orangered colored complex with the ferrous ion, which is measured in an automatic photometer Titertek Multiskan Ascent at a wavelength 408 nm. The concentration of ascorbic acid is also determined as described [13] . In this method, ascorbic acid is oxidized to dehydroascorbic acid and is later coupled with 2,4-dinitrophenylhydrazine. The coupling reaction forms 2,4-dinitrophenylosazone of dehydroascorbic acid, a light brown crystalline compound. When treated with 85% H 2 SO 4 , osazone is rearranged to form a reddish colored compound. The color of the standard and the eluates is measured in triplicates in a 96 well plate at a wavelength of 570 nm in an automatic photometer (Titertek Multiskan Ascent). The pH of the eluates is measured by pHydrion Paper (Micro Essential Laboratory, B'klyn, NY 11210) and confirmed by a Techne Model 3505 pH meter. The study protocol (#0400-192) for the collection of human semen and cervical mucus was approved by the institutional review board (IRB). Semen samples from male subjects at Center of Male Reproduction and Microbiology, of Weill Cornell Medical College of Cornell University underwent semen analysis sperm penetration tests according to World Health Organization guidelines [14] . Cervical mucus was also collected at the time of egg retrieval from female subjects stimulated by gonadotropins undergoing in vitro fertilization at the Center of Reproduction Medicine and Fertility of Weill Cornell Medical College/NY-Presbyterian Hospital. To test the speromiostatic affectivity, 50 µl of human semen is mixed with 50 µl of daily eluates of the IVR. Using a stop watch, the time is recorded when all the sperm are immobilized as observed under Diaphot-TMD Nikon Phase Contrast 2 high magnification microscope. A small amount of cervical mucus is plated on a glass cover slide and covered with a glass slip and incubated for 5 minutes. 10 µl of semen sample are added at each corner of the cover slip. The slides are incubated for 15 minutes, and then examined under the microscope to observe the sperm mobility prior to and after the addition of the IVR eluates.
Effect of IVR eluates on vaginal flora [5]:
Vaginal swabs from normal subjects are placed directly into culture tubes containing the eluate of the IVR and incubated for 24 hours to allow vaginal flora to react with the eluate. The eluate is then plated on agar and incubated for 96 hours to allow for bacterial growth. Effect of the eluate on the vaginal flora is determined by examining the plate and comparing it with the saline control.
Results
Comparison of daily eluates of IVR initially and after one year of storage
The IVR after one year of shelf life retained its flexibility and physical and mechanical properties (Figures 2 and 3) . The daily release rate of non-hormonal contraceptives of the intra-vaginal rings (IVR) is also efficacious in vitro after a year of storage. The daily eluates of the IVR in either phosphate buffer saline (PBS) or vaginal fluid stimulant [11] 
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Discussion
With the world's population at 7 billion and increasing, it is imperative to find a global balance between people and available resources. Lack of family planning is one of the pivotal causes of socio-economic issues that adversely affect maternal-fetal health, quality of life, and exposure to infectious diseases. Similarly, sexually active women not using contraception continue to be at risk for both unintended pregnancy and sexually transmitted diseases (STDs), including HIV. The intra-vaginal ring (IVR) is incorporated with non-hormonal contraceptives, namely ferrous gluconate, L-ascorbic acid, and mixtures of polyamino-polycarboxylic acid (Ampholines) or Poly L-Glutamic Acid (PLGA):sodium bicarbonate buffer to sustain a pH of 4.0. The compounds utilized are non-hormonal and are FDA approved for human use [5, 6] . The contraceptives are delivered locally and bypass the systemic route to be effective, thus avoid adverse effects of long term use of hormones. In addition, anti-HIV agents, such as tenofovir (PAMPA) and Boc-lysinated betulonic acid (Boc-LBA) which are soluble in aqueous medium [15] , may also be incorporated into the IVR. These microbicides act at different sites of viral life cycle, have low systemic absorption, and are nontoxic to the vaginal mucosa, thus they have the highest potential in preventing sexual transmission of HIV when used in combination at low doses to minimize the drug resistance [7] . The IVR may allow a compliant, safe, and effective method that can empower women for protection against undesired pregnancy, HIV, and/or pelvic infections.
During the development of the IVR, three objectives were identified as being necessary to inhibit sperm from fertilizing the ovum. The basis for localized non-hormonal contraception by ferrous gluconate, ascorbic acid, and a pH modifier, is to cause complete spermiostasis in less than a minute. Human spermatozoa are enriched with unsaturated fatty acids susceptible to lipid peroxidation, which is a type of cellular damage involving the formation of free oxygen radicals. When the bilayer of sperm tails are exposed to ferrous ion, the propagation of lipid peroxidation leads to continuous formation and decomposition of lipid peroxides and complete spermiostasis [16] [17] [18] [19] [20] . Any systemic absorption of ferrous gluconate may compensate for the loss of blood during menstruation in undernourished or malnourished women. Ascorbic acid is a vitamin and reduces the disulfide bonds in mucopolysaccharides of the cervical mucus to increase its viscosity to change it from an open cellular structure, found at midcycle of the menstrual period, to the closed structure in order to form an impenetrable barrier for sperm motility. A mixture of polyamino-polycarboxylic acid (ampholines) and/or Poly L-Glutamic Acid (PLGA) sodium bicarbonate buffer sustain the vaginal pH at 4, which is healthy for vaginal flora, but lethal to sperm [21] . The IVR allows for coital independence without affecting normal gonadal functions. The contraceptive agents are released by the IVR over a 30 day period, act locally, and prevent undesired pregnancy.
To inhibit the heterosexual transmission of HIV infection, the IVR can simultaneously deliver microbicides along with non-hormonal contraceptives to protect women from both undesired pregnancy and/or HIV infection.
The efficacy of these non-hormonal contraceptives has been amply demonstrated in vitro on human sperm and cervical mucus, as well as in vivo in rabbits [5] . In another study, women who used the formulation for 4 weeks showed complete spermiostasis with no adverse effects, irritation, or inflammation of the vaginal mucosa or phallus skin [22] . Safe and reliable use of the IVR will require the cooperation of both sexual partners. The IVR will also be cost effective for developing countries where inability of family planning often leads to insufficient nutrition and susceptibility to infectious diseases due to an overall decrease in quality of life.
